Summary
4.52 -0.26(-5.35%)03/13/2026
Larimar Therapeutics, Inc. (LRMR)
LRMR reported last earnings on 2025-11-05 after the market. An EPS of $-0.61 was observed compared to an estimated EPS of $-0.39, resulting in a surprise value of $-0.22. A revenue of $0 million was observed compared to an estimated revenue of $0 million, resulting in a surprise value of $0 Million.
Larimar Therapeutics, Inc. (LRMR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -5.35 | 7.42 | -16.59 | -6.46 | 97.81 | -41.42 | -83.33 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C+ |
| Recommended Rating | Sell |
| DCF | Neutral |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Neutral |
| P/E | Strong Sell |
| P/B | Neutral |
Earnings
| Trading Data | ||
| Close | 4.52 | |
| Open | 4.87 | |
| High | 5.01 | |
| Low | 4.45 | |
| Volume | 3,484,877 | |
| Change | -0.26 | |
| Change % | -5.35 | |
| Avg Volume (20 Days) | 1,465,574 | |
| Volume/Avg Volume (20 Days) Ratio | 2.38 | |
| 52 Week Range | 1.65 - 6.91 | |
| Price vs 52 Week High | -34.66% | |
| Price vs 52 Week Low | 173.64% | |
| Range | 0.00 | |
| Gap Up/Down | -0.15 | |
Profitibility | ||
| Market Capitalization (Mln) | 297 | |
| Revenue per share | 0.0000 | |
| Net Income per share | -1.6853 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -2.7266 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
03/15 02:06 EST - defenseworld.net
Investors Buy Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR)
Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) was the target of some unusual options trading activity on Friday. Investors purchased 3,011 call options on the company. This represents an increase of approximately 250% compared to the average daily volume of 861 call options. Larimar...
Investors Buy Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR)
Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) was the target of some unusual options trading activity on Friday. Investors purchased 3,011 call options on the company. This represents an increase of approximately 250% compared to the average daily volume of 861 call options. Larimar...
03/08 12:00 EST - investorplace.com
2 Breakout Stocks to Buy Immediately
Tom Yeung here with your Sunday Digest . In 2015, I visited the observatory at One World Trade Center – the newly opened viewing deck on the Western Hemisphere's tallest building.
2 Breakout Stocks to Buy Immediately
Tom Yeung here with your Sunday Digest . In 2015, I visited the observatory at One World Trade Center – the newly opened viewing deck on the Western Hemisphere's tallest building.
03/06 11:30 EST - zacks.com
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.
03/04 16:05 EST - globenewswire.com
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in...
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in...
03/03 17:34 EST - gurufocus.com
Market Today: Stocks Slide, Oil Majors Rally, Big Deals and FDA Setbacks
Guru Stock PicksKen Fisher has made the following transactions:Reduce in DEO by 23.8%Sold out in VSHAdd in AMKR by 204.55%New position in BROChuck Royce has mad
Market Today: Stocks Slide, Oil Majors Rally, Big Deals and FDA Setbacks
Guru Stock PicksKen Fisher has made the following transactions:Reduce in DEO by 23.8%Sold out in VSHAdd in AMKR by 204.55%New position in BROChuck Royce has mad
03/03 07:38 EST - gurufocus.com
First Look: Iran Shock Roils Markets; Target Beats, Amazon Buys
Stock News Hormuz disruption risks energy shock: Exxon Mobil (XOM) and global markets face rising supply risks as Iran claims to have shut the Strait of Hormuz;
First Look: Iran Shock Roils Markets; Target Beats, Amazon Buys
Stock News Hormuz disruption risks energy shock: Exxon Mobil (XOM) and global markets face rising supply risks as Iran claims to have shut the Strait of Hormuz;
02/25 20:59 EST - globenewswire.com
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its upsized underwritten public offering of 20,000,000...
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its upsized underwritten public offering of 20,000,000...
02/25 16:01 EST - globenewswire.com
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of $75 million of...
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of $75 million of...
02/25 14:30 EST - benzinga.com
Laminar Therapeutics Stock Is Popping Today: What's Going On?
Larimar Therapeutics Inc (NASDAQ: LRMR) shares are jumping on Wednesday after multiple analysts reiterated their bullish outlook.
Laminar Therapeutics Stock Is Popping Today: What's Going On?
Larimar Therapeutics Inc (NASDAQ: LRMR) shares are jumping on Wednesday after multiple analysts reiterated their bullish outlook.
02/24 12:12 EST - benzinga.com
Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation
The designation covers adults and children with the rare disease and was based on data from an ongoing open-label study. Here's what investors need to know.
Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation
The designation covers adults and children with the rare disease and was based on data from an ongoing open-label study. Here's what investors need to know.
02/24 07:00 EST - globenewswire.com
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA's review of available clinical data from open label study FDA written communications after recent START meeting continue to align with use of skin FXN to support BLA submission...
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA's review of available clinical data from open label study FDA written communications after recent START meeting continue to align with use of skin FXN to support BLA submission...
01/18 03:10 EST - defenseworld.net
Head-To-Head Survey: Oncology Pharma (OTCMKTS:ONPH) vs. Larimar Therapeutics (NASDAQ:LRMR)
Oncology Pharma (OTCMKTS:ONPH - Get Free Report) and Larimar Therapeutics (NASDAQ: LRMR - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings,...
Head-To-Head Survey: Oncology Pharma (OTCMKTS:ONPH) vs. Larimar Therapeutics (NASDAQ:LRMR)
Oncology Pharma (OTCMKTS:ONPH - Get Free Report) and Larimar Therapeutics (NASDAQ: LRMR - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings,...
01/16 06:17 EST - seekingalpha.com
Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care
Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich's Ataxia's root cause, with a mechanism that delivers missing frataxin, potentially supplanting current...
Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care
Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich's Ataxia's root cause, with a mechanism that delivers missing frataxin, potentially supplanting current...
01/14 14:36 EST - seekingalpha.com
Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
12/23 01:12 EST - defenseworld.net
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of “Moderate Buy” by Analysts
Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and eight have assigned...
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of “Moderate Buy” by Analysts
Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and eight have assigned...
12/18 08:00 EST - globenewswire.com
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in...
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in...
11/05 07:00 EST - globenewswire.com
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriers Consistent directional improvement across mFARS, FARS-ADL, 9-HPT and MFIS after 1-year in OL study reinforces the potential of...
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriers Consistent directional improvement across mFARS, FARS-ADL, 9-HPT and MFIS after 1-year in OL study reinforces the potential of...
11/01 04:11 EST - defenseworld.net
Ethic Inc. Invests $187,000 in Larimar Therapeutics, Inc. $LRMR
Ethic Inc. purchased a new stake in shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 61,723 shares of the company's stock, valued at approximately $187,000....
Ethic Inc. Invests $187,000 in Larimar Therapeutics, Inc. $LRMR
Ethic Inc. purchased a new stake in shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 61,723 shares of the company's stock, valued at approximately $187,000....
10/30 18:00 EST - businesswire.com
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR) resulting from allegations that Larimar Therapeutics may have issued materially misleading...
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR) resulting from allegations that Larimar Therapeutics may have issued materially misleading...
10/28 10:00 EST - prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Market News
×
Loading news…